Precision Medicine News and Updates | Precision Medicine Online
WEBThe adaptive basket trial, which matches patients to treatments based on complex biomarker signatures, could help shape future Phase III clinical trials. Three months after treatment with troculeucel, two patients in the Phase I portion went from having moderate to mild symptoms of dementia. Precision Medicine Online provides the latest news ...
Genetic Counselors Can Help Patients Sort Concerns, Set …
WEB1 day ago — NEW ORLEANS – Genetic counselors should help patients set realistic expectations when sorting through the risks and benefits of gene therapy, according to panelists at the National Society of Genetic Counselors annual meeting Saturday. As such, patients must grapple with whether this is a ...
Aptadir Therapeutics Launches With $1.6M to Advance RNA …
WEB1 day ago — NEW YORK – Aptadir Therapeutics launched on Tuesday with the goal of advancing its RNA inhibitor-based drug candidates for cancers and genetic conditions, beginning with Aptadir Ce-49, its lead candidate for myelodysplastic syndrome (MDS). The Milan-based firm is developing what it calls DiRs ...
AstraZeneca, Daiichi Sankyo Hoping to Sway FDA of Dato-DXd …
WEB2 days ago — NEW YORK – In the Phase III TROPION-Breast01 clinical trial, patients with previously treated hormone receptor (HR)-positive, HER2-negative or -low breast cancer did not experience a statistically significant overall survival benefit from datopotamab deruxtecan (Dato-DXd) compared to chemotherapy, a finding that AstraZeneca and Daiichi Sankyo will share with regulators.
KSQ Therapeutics Gets FDA Clearance to Begin Phase I/II Trial of …
WEB1 day ago — NEW YORK – KSQ Therapeutics said on Tuesday it has been cleared by the US Food and Drug Administration to begin a Phase I/II study of its engineered tumor-infiltrating lymphocyte (TIL) treatment KSQ-004EX in certain advanced solid tumors. Lexington, Massachusetts-based KSQ will enroll 141 patients ...
Precision Oncology News - Precision Medicine Online
WEBSep 16, 2024. AI-Driven Genomic Test Shows Promise in De-Escalating Neoadjuvant TNBC Therapy. Sep 15, 2024. TORL BioTherapeutics' CLDN6-Targeting Antibody-Drug Conjugate Demonstrates Encouraging Early Results. Sep 15, 2024. Bristol Myers Squibb's Krazati Bests Chemo in KRAS-Mutant NSCLC With Brain Metastases. Sep 15, 2024.
Breaking News - Precision Medicine Online
WEBSep 13, 2024 — Population Testing for BRCA1/2 Appears Cost-Effective in Younger Canadian Women. Using simulated data for 1 million women, researchers found that population-based BRCA1/2 testing would be cost-effective, particularly in 30-year-old women. Sep 13, 2024.
Price of Precision: Patients, Oncologists Highlight Costs of Fighting ...
WEBJun 1, 2023 — NEW YORK — The side effects of cancer treatments are notoriously arduous, but the market entry of high-priced biomarker-informed drugs and immunotherapies has introduced another type of toxicity to the cancer lexicon — financial toxicity.
Genomics Research & Discovery | Precision Medicine Online
WEBMay 30, 2024 — BePRECISE Consortium Publishes Checklist for Reporting Precision Medicine Research Findings
Precision Oncology in 2022: New Drugs and Tests Amid Ongoing …
WEBJan 4, 2023 — NEW YORK – Looking back at 2022, plenty of new CAR T-cell, radioligand, and biomarker-defined treatments entered the market, as did new tissue and liquid biopsy tests to identify cancer patients eligible for these therapies.